[Explanation] The China International Import Expo (hereinafter referred to as the CIIE), which has entered its fifth year, has been fruitful.

On November 6, the reporter saw many familiar "old faces" in the "Exhibitor-to-Investor" zone set up for the first time at this CIIE.

　　They benefit from the continuous release of the spillover effect of the Expo, and they are also vivid examples of exhibitors turning investors into the "fast lane".

Tencel Group, which has settled in this special area, brought the world's first new products at this CIIE, and reviewed the "win-win" story with the CIIE in an all-round way.

　　[Concurrent] Zeng Senhong, President of Tencel Group China

　　The CIIE is a huge "testing ground" - new products and new technologies are commercialized, and exhibits become commodities; the CIIE is also a strong "magnetic field" - attracting outstanding companies from all over the world to take root in China and exhibitors to become investors.

Our story with the CIIE is one of the vivid examples.

Among them, what impressed me was that during the CIIE last year, we conducted product research and taste tests for consumers at the booth of Tencel Group, and obtained first-hand feedback to help us better develop new products.

　　[Explanation] The two prescription drugs that Bayer exhibited at this CIIE were exhibited as future innovative products at the last two CIIEs. They won widespread attention with their new mechanism of action, and were awarded in China in the first half of this year. approve.

This time, it participated in the exhibition as a commodity, and it was submitted at the same time globally and approved at the same time around the world.

　　[Concurrent] Chen Wanjun, Vice President of Strategic Marketing of Bayer Group's Prescription Drug Division

　　The CIIE witnessed the entire process of (our) two products being developed, submitted simultaneously, and approved at the same time at home and abroad.

They will be exhibited as commodities for the first time at the CIIE, which also shows the "spillover effect" and "window effect" of the CIIE.

　　[Explanation] Also benefiting is Ailang Medical. After completing its "China debut" last year, its new-generation full-core biopsy gun, one of its blockbuster new products, was approved in China in June this year and completed the "exhibit change". The "transformation" of commodities" was officially announced at this year's CIIE.

　　[Concurrent] Wen Hongwei, head of the sales department of Ailang China

　　After this product was exhibited last year (at the CIIE), we also actively promoted our registration in China.

Finally, we got the registration certificate this year, which means that we can turn this product into a commodity, sell it in the market, and serve more patients.

(This) also allows us to see the real embodiment and implementation of a (China) speed that promotes our products from exhibits to commodities at the CIIE.

　　[Explanation] Since its "first show" at the first CIIE, Sanofi's new indications for moderate-to-severe atopic dermatitis have been expanded to infants and young children, and the "China Speed" has started: in 2020 Approved, 2 years earlier than the original plan, and it took only 25 days to achieve the approval for drug supply... Sanofi also announced the signing of strategic cooperation agreements with partners such as Shenzhen CDC and Health Cloud at this CIIE. Work together to build a local innovation ecosystem.

Today, more and more exhibitors at the CIIE are accelerating their "transformation" as investors, laying out in the Chinese market, taking root in this hot investment land, and resonating with the new pattern of China's development at the same frequency.

　　Reporter Xu Yinkang Yuzhan reported from Shanghai

Responsible editor: [Yu Xiao]